SAN FRANCISCO–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the company’s clinical development program for advanced fibrosis due to nonalcoholic steatohepatitis (NASH). Data presented support the ongoing development of the company’s investigational compounds, evaluate the utility of noninvasive tests for the identification of patients with advanced fibrosis, …
Tag Archives: fibrosis
November, 2018
October, 2018
-
18 October
AbbVie and Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases
NORTH CHICAGO, Ill. and WALTHAM, Mass., Oct. 18, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Morphic Therapeutic, a biotechnology company developing oral integrin therapies, announced today that the companies have entered into a research and development collaboration designed to advance a number of Morphic’s oral integrin therapeutics for fibrosis-related indications. …
October, 2017
-
13 October
Bristol-Myers Squibb Extends Partnership with Target PharmaSolutions for TARGET-NASH
CHAPEL HILL, N.C, Oct. 12, 2017 /PRNewswire/ — TARGET PharmaSolutions, Inc., a real-world clinical data company, is pleased to announce that Bristol-Myers Squibb (BMY) has extended its strategic partnership for TARGET-NASH to a multi-year agreement. Bristol-Myers Squibb is committed to the discovery and development of medicines for fibrosis, including NASH. …
April, 2017
-
21 April
Gilead Announces Positive Proof-of-Concept Data for its NASH Candidate
FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from an open-label, proof-of-concept study evaluating GS-0976, an investigational inhibitor of Acetyl-CoA carboxylase (ACC), in patients with nonalcoholic steatohepatitis (NASH). The data, from ten patients treated with GS-0976 20 mg taken orally once daily for 12 weeks, indicated that treatment …
-
17 April
Bristol-Myers Squibb and Nordic Bioscience Collaborate for Fibrosis Biomarker Technology
NEW YORK & HERLEV, Denmark–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Nordic Bioscience, a Danish company specializing in biomarker technologies, today announced a collaboration agreement to develop biomarker technology to potentially aid in the diagnosis and monitoring of fibrotic diseases including Non-alcoholic steatohepatitis (NASH). Nordic Bioscience has over 25 years’ experience …
December, 2016
-
7 December
Coffee: Pour Another Cup, Guilt-Free
Coffee is not only a welcome way that 54% of Americans start their day, it also offers liver benefits to coffee fans. I have shared good news about coffee and liver health in several past blogs, including last year’s The Buzz of Caffeine in which coffee’s ability to protect against …
November, 2015
-
10 November
Guided by Fibrosis Stage
When to start treatment for hepatitis C can be a hotly debated topic, with sicker patients generally moved to the front of the line. However, the question remains: “how can we identify who are the ‘sicker patients’?” An effective way to identify which hepatitis C patients should get the most …
April, 2015
-
29 April
Celgene Inks Cancer Deals with Agios Pharmaceuticals and Northern Biologics
Celgene is enhancing its oncology pipeline, striking separate cancer-focused deals with Agios Pharmaceuticals and startup Northern Biologics. Agios announced it is expanding its partnership with cancer metabolism partner Celgene. The companies have entered into a new joint worldwide development and profit share collaboration for AG-881, a small molecule that has …